Carisma Therapeutics Inc (CARM)

$1.41

-0.01

(-0.7%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Carisma Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 3.24M → 4.28M (in $), with an average increase of 6.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -21.40M → -20.95M (in $), with an average increase of 1.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 129.6%

Performance

  • $1.39
    $1.47
    $1.41
    downward going graph

    1.42%

    Downside

    Day's Volatility :5.12%

    Upside

    3.75%

    downward going graph
  • $1.35
    $9.77
    $1.41
    downward going graph

    4.26%

    Downside

    52 Weeks Volatility :86.18%

    Upside

    85.57%

    downward going graph

Returns

PeriodCarisma Therapeutics IncIndex (Russel 2000)
3 Months
-42.74%
0.0%
6 Months
-44.96%
0.0%
1 Year
-71.08%
0.0%
3 Years
-61.31%
-20.1%

Highlights

Market Capitalization
58.6M
Book Value
$0.26
Earnings Per Share (EPS)
-1.12
Wall Street Target Price
8.83
Profit Margin
0.0%
Operating Margin TTM
-574.33%
Return On Assets TTM
-46.36%
Return On Equity TTM
-167.51%
Revenue TTM
15.1M
Revenue Per Share TTM
0.37
Quarterly Revenue Growth YOY
4.7%
Gross Profit TTM
0.0
EBITDA
-81.4M
Diluted Eps TTM
-1.12
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.26
EPS Estimate Next Year
-1.24
EPS Estimate Current Quarter
-0.43
EPS Estimate Next Quarter
-0.33

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Carisma Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 526.24%

Current $1.41
Target $8.83

Company Financials

FY20Y/Y Change
Revenue
11.2M
-
Net Income
-28.3M
↓ 73.66%
Net Profit Margin
-252.05%
-
FY21Y/Y Change
Revenue
26.5M
↑ 136.24%
Net Income
-40.8M
↑ 43.98%
Net Profit Margin
-153.61%
↑ 98.44%
FY22Y/Y Change
Revenue
9.8M
↓ 62.95%
Net Income
-61.2M
↑ 50.16%
Net Profit Margin
-622.6%
↓ 468.99%
FY23Y/Y Change
Revenue
14.9M
↑ 51.71%
Net Income
-86.9M
↑ 41.9%
Net Profit Margin
-582.34%
↑ 40.26%
Q4 FY22Q/Q Change
Revenue
3.7M
↑ 44.72%
Net Income
12.3M
↓ 167.17%
Net Profit Margin
329.94%
↑ 1040.84%
Q1 FY23Q/Q Change
Revenue
3.2M
↓ 13.08%
Net Income
-24.6M
↓ 300.18%
Net Profit Margin
-759.85%
↓ 1089.79%
Q2 FY23Q/Q Change
Revenue
3.6M
↑ 9.77%
Net Income
-19.9M
↓ 19.34%
Net Profit Margin
-558.31%
↑ 201.54%
Q3 FY23Q/Q Change
Revenue
3.8M
↑ 7.5%
Net Income
-21.4M
↑ 7.68%
Net Profit Margin
-559.26%
↓ 0.95%
Q4 FY23Q/Q Change
Revenue
4.3M
↑ 12.07%
Net Income
-21.0M
↓ 2.08%
Net Profit Margin
-488.65%
↑ 70.61%
Q1 FY24Q/Q Change
Revenue
4.3M
↑ 0.0%
Net Income
-21.0M
↑ 0.0%
Net Profit Margin
-488.65%
↑ 0.0%
FY18Y/Y Change
Total Assets
111.6M
↑ 48.56%
Total Liabilities
67.4M
↑ 18.03%
FY19Y/Y Change
Total Assets
114.4M
↑ 2.51%
Total Liabilities
141.1M
↑ 109.44%
FY20Y/Y Change
Total Assets
58.5M
↓ 48.88%
Total Liabilities
8.3M
↓ 94.11%
FY21Y/Y Change
Total Assets
35.4M
↓ 39.37%
Total Liabilities
9.4M
↑ 13.4%
FY22Y/Y Change
Total Assets
72.2M
↑ 103.54%
Total Liabilities
101.3M
↑ 974.55%
FY23Y/Y Change
Total Assets
89.6M
↑ 24.12%
Total Liabilities
63.0M
↓ 37.77%
Q4 FY22Q/Q Change
Total Assets
271.6M
↑ 36.0%
Total Liabilities
113.4M
↑ 226.95%
Q1 FY23Q/Q Change
Total Assets
156.1M
↓ 42.52%
Total Liabilities
70.1M
↓ 38.24%
Q2 FY23Q/Q Change
Total Assets
133.0M
↓ 14.81%
Total Liabilities
66.3M
↓ 5.36%
Q3 FY23Q/Q Change
Total Assets
106.8M
↓ 19.72%
Total Liabilities
60.5M
↓ 8.78%
Q4 FY23Q/Q Change
Total Assets
89.6M
↓ 16.14%
Total Liabilities
63.0M
↑ 4.19%
Q1 FY24Q/Q Change
Total Assets
89.6M
↑ 0.0%
Total Liabilities
63.0M
↑ 0.0%
FY20Y/Y Change
Operating Cash Flow
-27.0M
↓ 28.01%
Investing Cash Flow
-440.0K
-
Financing Cash Flow
72.3M
↑ 104.37%
FY21Y/Y Change
Operating Cash Flow
-37.3M
↑ 38.19%
Investing Cash Flow
-1.9M
↑ 325.23%
Financing Cash Flow
16.0M
↓ 77.91%
Q4 FY22Q/Q Change
Operating Cash Flow
2.7M
↓ 132.23%
Investing Cash Flow
13.8M
↓ 719.79%
Financing Cash Flow
1000.0
↓ 100.48%
Q1 FY23Q/Q Change
Operating Cash Flow
-25.5M
↓ 1052.41%
Investing Cash Flow
35.8M
↑ 158.91%
Financing Cash Flow
67.7M
↑ 6774100.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-18.5M
↓ 27.36%
Investing Cash Flow
35.8M
↑ 0.0%
Financing Cash Flow
-3.6M
↓ 105.36%

Technicals Summary

Sell

Neutral

Buy

Carisma Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Carisma Therapeutics Inc
Carisma Therapeutics Inc
-24.06%
-44.96%
-71.08%
-61.31%
-61.31%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Carisma Therapeutics Inc
Carisma Therapeutics Inc
NA
NA
NA
-1.26
-1.68
-0.46
NA
0.26
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Carisma Therapeutics Inc
Carisma Therapeutics Inc
Buy
$58.6M
-61.31%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Company Information

eleven biotherapeutics is focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics to improve human health and treat disease. eleven biotherapeutics' scientists are engineering protein-based drugs using newly available structural information and the company’s unique molecular understanding of clinical effects to create the next generation of protein-based medicines to treat important diseases with unmet needs, such as inflammatory conditions and coagulation disorders.

Organization
Carisma Therapeutics Inc
Employees
107
CEO
Mr. Steven Kelly
Industry
Miscellaneous

Discover More

FAQs